The evidence is overwhelming that the androgen receptor is a valuable target for prostate cancer, however, an alternative strategy should be explored to disrupt the androgen receptor as opposed to traditional antagonists at the ligand binding domain. This evidence concerns the gene AR and prostate cancer.